Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIAO@SAH trial of Cinryze for aneurysmal subarachnoid hemorrhage
NL-OMON51205Phase 2Not yet recruiting
- Sponsor
- Haaglanden Medical Centre
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in subarachnoid hemorrhage (SAH) and brain hemorrhage (ICH) comparing Cinryze with Placebo (2 arms). Primary endpoints: Delayed cerebral ischemia and Complication rate during hospitalization. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
c1-esterase inhibitor
03
Conditions
subarachnoid hemorrhage (SAH)brain hemorrhage (ICH)
Beyond the preview
Go deeper on NL-OMON51205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51205.